Curl Bio

Curl Bio LLC develops drugs for the interrelated set of disorders involving type-II diabetes, obesity, metabolic syndrome and associated complications. Our current strategy for drug development uses a combination of phenotypic and molecular target driven approaches with core competencies in pancreatic islet technologies, fatty liver disease, and metabolic regulation in muscle tissue.